# Neoadjuvant Adebrelimab With Dalpiciclib for Resectable Esophageal Squamous Cell Carcinomas

> **NCT06225921** · PHASE1 · UNKNOWN · sponsor: **West China Hospital** · enrollment: 6 (estimated)

## Conditions studied

- Esophageal Squamous Cell Carcinoma

## Interventions

- **DRUG:** Adebrelimab
- **DRUG:** Dalpiciclib 100mg
- **DRUG:** Dalpiciclib 150mg

## Key facts

- **NCT ID:** NCT06225921
- **Lead sponsor:** West China Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2023-12-29
- **Primary completion:** 2025-01-15
- **Final completion:** 2025-01-15
- **Target enrollment:** 6 (ESTIMATED)
- **Last updated:** 2024-03-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06225921

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06225921, "Neoadjuvant Adebrelimab With Dalpiciclib for Resectable Esophageal Squamous Cell Carcinomas". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT06225921. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*